Cargando…

Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma

BACKGROUND: Transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) is often repeated until unTACEable progression (UTP) occurs. There is little data on the various reasons for stopping TACE and its consequences for subsequent treatment and survival. AIM: To asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Labeur, Tim A., Takkenberg, R. Bart, Klümpen, Heinz-Josef, van Delden, Otto M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344387/
https://www.ncbi.nlm.nih.gov/pubmed/30488302
http://dx.doi.org/10.1007/s00270-018-2118-6
_version_ 1783389413097603072
author Labeur, Tim A.
Takkenberg, R. Bart
Klümpen, Heinz-Josef
van Delden, Otto M.
author_facet Labeur, Tim A.
Takkenberg, R. Bart
Klümpen, Heinz-Josef
van Delden, Otto M.
author_sort Labeur, Tim A.
collection PubMed
description BACKGROUND: Transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) is often repeated until unTACEable progression (UTP) occurs. There is little data on the various reasons for stopping TACE and its consequences for subsequent treatment and survival. AIM: To assess the impact of the various reasons of UTP on survival and consequences for subsequent treatments. METHODS: Consecutive HCC patients who underwent TACE between 2003 and 2016 were analyzed retrospectively for the reason of TACE discontinuation. UTP was defined according to the EASL guidelines, considering radiological pattern of progression, liver function and performance status (PS). Overall and post-progression survival (OS, PPS) for different reasons of TACE discontinuation were compared. The correlation between time to untreatable progression by chemoembolization (TTUPc) and OS was analyzed. RESULTS: One hundred and sixty-six patients (BCLC-A 40%, BCLC-B 54%, BCLC-C: 7%) were included, undergoing a median of 2 TACE procedures with a median OS of 22.1 months (95% CI 17.4–26.7). UTP occurred in 116 patients (70%) after a median TTUPc of 11.6 months (95% CI 7.8–15.4). There was a strong positive correlation (ρ = 0.816, p < 0.001) between TTUPc and OS. The main reason of UTP was radiological progression (61%), which was mostly intrahepatic (75%). Hepatic decompensation and worsening of PS were independent predictors of OS and PPS. CONCLUSION: The majority of HCC patients treated with TACE have UTP due to intrahepatic tumor progression with preserved liver function and PS, making them potential candidates for subsequent liver-directed or systemic treatment. TTUPc may be a valuable surrogate endpoint for OS in patients treated with TACE. LEVEL OF EVIDENCE: Level II, prognosis study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2118-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6344387
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-63443872019-02-08 Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma Labeur, Tim A. Takkenberg, R. Bart Klümpen, Heinz-Josef van Delden, Otto M. Cardiovasc Intervent Radiol Clinical Investigation BACKGROUND: Transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) is often repeated until unTACEable progression (UTP) occurs. There is little data on the various reasons for stopping TACE and its consequences for subsequent treatment and survival. AIM: To assess the impact of the various reasons of UTP on survival and consequences for subsequent treatments. METHODS: Consecutive HCC patients who underwent TACE between 2003 and 2016 were analyzed retrospectively for the reason of TACE discontinuation. UTP was defined according to the EASL guidelines, considering radiological pattern of progression, liver function and performance status (PS). Overall and post-progression survival (OS, PPS) for different reasons of TACE discontinuation were compared. The correlation between time to untreatable progression by chemoembolization (TTUPc) and OS was analyzed. RESULTS: One hundred and sixty-six patients (BCLC-A 40%, BCLC-B 54%, BCLC-C: 7%) were included, undergoing a median of 2 TACE procedures with a median OS of 22.1 months (95% CI 17.4–26.7). UTP occurred in 116 patients (70%) after a median TTUPc of 11.6 months (95% CI 7.8–15.4). There was a strong positive correlation (ρ = 0.816, p < 0.001) between TTUPc and OS. The main reason of UTP was radiological progression (61%), which was mostly intrahepatic (75%). Hepatic decompensation and worsening of PS were independent predictors of OS and PPS. CONCLUSION: The majority of HCC patients treated with TACE have UTP due to intrahepatic tumor progression with preserved liver function and PS, making them potential candidates for subsequent liver-directed or systemic treatment. TTUPc may be a valuable surrogate endpoint for OS in patients treated with TACE. LEVEL OF EVIDENCE: Level II, prognosis study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2118-6) contains supplementary material, which is available to authorized users. Springer US 2018-11-28 2019 /pmc/articles/PMC6344387/ /pubmed/30488302 http://dx.doi.org/10.1007/s00270-018-2118-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Investigation
Labeur, Tim A.
Takkenberg, R. Bart
Klümpen, Heinz-Josef
van Delden, Otto M.
Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title_full Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title_fullStr Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title_full_unstemmed Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title_short Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
title_sort reason of discontinuation after transarterial chemoembolization influences survival in patients with hepatocellular carcinoma
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344387/
https://www.ncbi.nlm.nih.gov/pubmed/30488302
http://dx.doi.org/10.1007/s00270-018-2118-6
work_keys_str_mv AT labeurtima reasonofdiscontinuationaftertransarterialchemoembolizationinfluencessurvivalinpatientswithhepatocellularcarcinoma
AT takkenbergrbart reasonofdiscontinuationaftertransarterialchemoembolizationinfluencessurvivalinpatientswithhepatocellularcarcinoma
AT klumpenheinzjosef reasonofdiscontinuationaftertransarterialchemoembolizationinfluencessurvivalinpatientswithhepatocellularcarcinoma
AT vandeldenottom reasonofdiscontinuationaftertransarterialchemoembolizationinfluencessurvivalinpatientswithhepatocellularcarcinoma